* Clearside Biomedical Inc CLSD.OQ reported a quarterly
adjusted
loss of 8 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -16 cents. The mean expectation of six analysts
for the quarter was for a loss of 9 cents per share. Wall Street
expected results to range from -15 cents to -5 cents per share.
* Revenue rose 1,822.7% to $6.35 million from a year ago;
analysts
expected $4.43 million.
* Clearside Biomedical Inc's reported EPS for the quarter
was a
loss of 8 cents.
* The company reported a quarterly loss of $4.83 million.
* Clearside Biomedical Inc shares had risen by 72.6% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Clearside
Biomedical Inc is $5.50
This summary was machine generated from LSEG data March 12 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.09 -0.08 Beat
Sep. 30 2023 -0.15 -0.15 Met
Jun. 30 2023 -0.14 -0.15 Missed
Mar. 31 2023 -0.14 -0.15 Missed